Dana Lukin MD PhD
Inflammatory Bowel Disease
Associate Professor of Medicine
1283 York Avenue9th FloorNew York, NY 10065
Overview of Dr. Lukin
Dr. Dana Lukin, based in New York, NY, specializes in Gastroenterology with a sub-specialty in Inflammatory Bowel Disease. His education includes both MD and PhD degrees from Icahn School of Medicine at Mount Sinai, with a residency in Internal Medicine at the same institution. He completed a fellowship in Gastroenterology at New York Presbyterian Hospital. Currently, he serves as an Attending Physician at New York-Presbyterian Hospital and as an Assistant Professor at Weill Cornell Medicine, after a tenure at Montefiore Medical Center. He possesses expertise in inflammatory bowel disease, ulcerative colitis, Crohn's disease, and endoscopy. Dr. Lukin has authored several notable publications in his field, and he is actively involved in clinical trials examining vaccination adherence among IBD patients and the effect of time-restricted feeding on Crohn's Disease.
Education & Training
- New York Presbyterian Hospital (Cornell Campus)Fellowship, Gastroenterology, 2010 - 2013
- Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 2007 - 2010
- Icahn School of Medicine at Mount SinaiClass of 2007, MD, PhD
Certifications & Licensure
- NY State Medical License 2008 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Gastroenterology
Clinical Trials
- The Impact of Time Restricted Feeding in Crohn's Disease Start of enrollment: 2021 Jan 14
- Education Intervention on Vaccination Adherence Among Inflammatory Bowel Disease (IBD) Patients Start of enrollment: 2021 Feb 04
Publications & Presentations
PubMed
- IgG-seq identifies immune-reactive enteric bacteria in Crohn's disease with spondyloarthritis.Grace A Maldarelli, Maeva Metz, Seun Oguntunmibi, Nancy Tran, Grace Xiang
Gut Microbes. 2025-12-01 - Safety of Immunosuppression in a Prospective Cohort of Inflammatory Bowel Disease Patients With a HIstoRy of CancEr: SAPPHIRE Registry.Steven H Itzkowitz, Yue Jiang, Cristina Villagra, Jean-Frederic Colombel, Keith Sultan
Clinical Gastroenterology and Hepatology. 2025-04-01 - Treat-to-target of endoscopic remission in patients with inflammatory bowel disease in symptomatic remission on advanced therapies (QUOTIENT): rationale, design and pr...Siddharth Singh, Jasmine D Nguyen, David I Fudman, Mark E Gerich, Samir A Shah
BMJ Open Gastroenterology. 2025-03-31
Journal Articles
- Correction: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY ConsortiumLeah Katta, Robert Hirten, Shannon Chang, Dana Lukin, Edward V Loftus, David Faleck, Arun Swaminath, William J Sandborn, Sashidhar Varma Sagi, Sunanda Kane, Prianka Ch..., Nature
- Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY ConsortiumGursimran Kochhar, Justin Hartke, Sashidhar Varma Sagi, Edward V Loftus, Joseph Meserve, Robert Hirten, David Faleck, Shannon Chang, Dana Lukin, Farhad Peerani, Leah K..., Nature
Press Mentions
- List of Advanced Rx Recommended For Moderate to Severe UC ExpandsFebruary 4th, 2025
- Inpatient Monitoring May Extend Hospital Stays in Acute Severe Ulcerative ColitisJuly 30th, 2024
- Upadacitinib Induction Provided Fast Symptom Relief in Ulcerative ColitisDecember 2nd, 2022
- Join now to see all
Professional Memberships
- Member
- Member
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: